Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

22 May 2011

Abstract excerpt

INTRODUCTION: Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are given in combination. METHODS: This unexpected effect is rationalized through computer models...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21600050
DOI: 10.1186/bcr2888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanismPMID 21600050Read ↗

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2Semantic proximity Read ↗

Dynamical rearrangement of human epidermal growth factor receptor 2 upon antibody binding: effects on the dimerizationSemantic proximity Read ↗

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer TherapySemantic proximity Read ↗

Fluorescence cross-correlation spectroscopy quantifies affinity, cooperativity, and kinetic stability in ternary protein complexesSemantic proximity Read ↗

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.Semantic proximity Read ↗

Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.Semantic proximity Read ↗

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interfaceSemantic proximity Read ↗

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complexSemantic proximity Read ↗

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.Semantic proximity Read ↗

Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and TrastuzumabSemantic proximity Read ↗

An anti-HER2 nanobody binds to its antigen HER2 via two independent paratopes.Semantic proximity Read ↗

Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.